董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher Missling | 男 | Chief Executive Officer,Director, President and Secretary | 61 | 395.91万美元 | 758.08 | 2026-02-23 |
| Athanasios Skarpelos | 男 | Director | 60 | 34.81万美元 | 164.53 | 2026-02-23 |
| Steffen Thomas | 男 | Director | 60 | 34.81万美元 | 39.38 | 2026-02-23 |
| Peter Donhauser | 男 | Director | 61 | 34.81万美元 | 29.38 | 2026-02-23 |
| Claus van der Velden | 男 | Director | 54 | 36.41万美元 | 28.88 | 2026-02-23 |
| Jiong Ma | 女 | Chair and Director | 62 | 36.41万美元 | 14.33 | 2026-02-23 |
| Axel Paeger | -- | Independent Director | -- | 未披露 | 未持股 | 2026-02-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Christopher Missling | 男 | Chief Executive Officer,Director, President and Secretary | 61 | 395.91万美元 | 758.08 | 2026-02-23 |
| Sandra Boenisch | 女 | Principal Financial Officer and Treasurer | 45 | 55.53万美元 | 32.28 | 2026-02-23 |
董事简历
中英对照 | 中文 | 英文- Christopher Missling
-
Christopher Missling在大型制药，生物技术产业和投资银行业务方面有着20多年的医疗行业经验。最近，从2007年3月到被公司任命之前，他曾担任纽约Brimberg & Co.医疗保健投资银行主管。此外， Missling还担任过Curis, Inc. NASDAQ：CRIS 和 ImmunoGen, Inc. （NASDAQ：IMGN）首席财务官。Missling持有Munich大学理学硕士和博士学位；Northwestern 大学Kellogg School of Management和WHU Otto Beisheim School of Management工商管理硕士学位。
Christopher Missling has over tnty years of healthcare indtry experience in big pharmaceutical, biotech and investment banking prior to joining Anavex. Most recently, from March 2007 until his appointment by Company, Dr. Missling served as the head of healthcare investment banking at Brimberg & Co. in New York, New York. In addition, Dr. Missling served as the Chief Financial Officer of Curis, Inc. (NASDAQ: CRIS) and ImmunoGen, Inc. (NASDAQ: IMGN). Dr. Missling earned his MS and PhD from the University of Munich and an MBA from Northstern University Kellogg School of Management and WHU Otto Beisheim School of Management. - Christopher Missling在大型制药，生物技术产业和投资银行业务方面有着20多年的医疗行业经验。最近，从2007年3月到被公司任命之前，他曾担任纽约Brimberg & Co.医疗保健投资银行主管。此外， Missling还担任过Curis, Inc. NASDAQ：CRIS 和 ImmunoGen, Inc. （NASDAQ：IMGN）首席财务官。Missling持有Munich大学理学硕士和博士学位；Northwestern 大学Kellogg School of Management和WHU Otto Beisheim School of Management工商管理硕士学位。
- Christopher Missling has over tnty years of healthcare indtry experience in big pharmaceutical, biotech and investment banking prior to joining Anavex. Most recently, from March 2007 until his appointment by Company, Dr. Missling served as the head of healthcare investment banking at Brimberg & Co. in New York, New York. In addition, Dr. Missling served as the Chief Financial Officer of Curis, Inc. (NASDAQ: CRIS) and ImmunoGen, Inc. (NASDAQ: IMGN). Dr. Missling earned his MS and PhD from the University of Munich and an MBA from Northstern University Kellogg School of Management and WHU Otto Beisheim School of Management.
- Athanasios Skarpelos
-
Athanasios Skarpelos是个体投资者，在私营和公共公司有着17年多的工作经验。在过去10年中，他主要关注涉及药物发现和药物开发项目生物技术公司。Skarpelos与公司约定担任一年顾问，2010年8月2日开始生效。他的经验促使他和欧洲以及北美的学术机构的研究者建立了关系。Skarpelos是Anavex创始人。
Athanasios Skarpelos is a self employed investor with over 25 years of experience working with private and public companies with a foc on biotechnology companies involved in drug discovery and drug development projects. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos is a founder of Anavex. - Athanasios Skarpelos是个体投资者，在私营和公共公司有着17年多的工作经验。在过去10年中，他主要关注涉及药物发现和药物开发项目生物技术公司。Skarpelos与公司约定担任一年顾问，2010年8月2日开始生效。他的经验促使他和欧洲以及北美的学术机构的研究者建立了关系。Skarpelos是Anavex创始人。
- Athanasios Skarpelos is a self employed investor with over 25 years of experience working with private and public companies with a foc on biotechnology companies involved in drug discovery and drug development projects. His experience has led to relationships with researchers at academic institutes in Europe and North America. Mr. Skarpelos is a founder of Anavex.
- Steffen Thomas
-
Steffen Thomas，他曾担任日本田制药公司（Takeda Pharmaceuticals，亚洲最大的制药公司和全球顶级公司）任职，担任内部专利律师。此前，他在Nycomed Pharma任职， 2011年Nycomed Pharma被Takeda以大约100亿美元收购他的法律实践包括起草专利申请、在国家和国际专利办公室进行专利申请，再侵权法院捍卫和挑战专利反对，上诉，实施专利无效诉讼和准备对化学技术领域的可专利性和侵权的提意见。他有小分子药物的专业经验。 他获得Munich大学的化学硕士和博士学位。
Steffen Thomas has over 25 years of experience as a European patent attorney and is currently practicing, since September 2011, at Epping Hermann Fischer, a major intellectual property law firm in Europe. Previoly, he worked for Japan based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in hoe patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately D $10 billion. Dr. Thomas' legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement cts, and preparing opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich. - Steffen Thomas，他曾担任日本田制药公司（Takeda Pharmaceuticals，亚洲最大的制药公司和全球顶级公司）任职，担任内部专利律师。此前，他在Nycomed Pharma任职， 2011年Nycomed Pharma被Takeda以大约100亿美元收购他的法律实践包括起草专利申请、在国家和国际专利办公室进行专利申请，再侵权法院捍卫和挑战专利反对，上诉，实施专利无效诉讼和准备对化学技术领域的可专利性和侵权的提意见。他有小分子药物的专业经验。 他获得Munich大学的化学硕士和博士学位。
- Steffen Thomas has over 25 years of experience as a European patent attorney and is currently practicing, since September 2011, at Epping Hermann Fischer, a major intellectual property law firm in Europe. Previoly, he worked for Japan based Takeda Pharmaceutical Company, the largest pharmaceutical company in Asia and a top firm worldwide, as an in hoe patent attorney. Prior to that, he worked for Nycomed Pharma, acquired by Takeda in 2011 for approximately D $10 billion. Dr. Thomas' legal practice covers drafting of patent applications, prosecuting patent applications before national and international patent offices, defending and challenging patents in opposition, appeal, and nullity proceedings, enforcing patents before the infringement cts, and preparing opinions on patentability and infringement in the technical field of chemistry. Dr. Thomas has particular expertise in small molecule pharmaceuticals. He holds MS and PhD degrees in Chemistry from the University of Munich.
- Peter Donhauser
-
Peter Donhauser在临床研究方面拥有20多年的专业知识，之后于2000年开始在私人执业中以综合医疗方法从事整骨医学。他曾在慕尼黑大学医院从事老年医学和神经肌肉骨骼疾病领域的工作。在此期间，他是多项3期研究的临床试验研究者，包括由默沙东 Sharp & Dohme、默沙东、勃林格曼海姆、罗氏、施维雅和赛诺菲赞助的研究。他在慕尼黑大学获得人类医学学位，并在费城整骨医学学院的德国美国整骨医学研究院（DAAO）获得整骨医学博士（D.O.），这是欧洲整骨医师名册（European Register for Osteopathic Physicians，简称EROP）的成员。
Peter Donhauser had more than 20 years of expertise in clinical research prior to practicing osteopathic medicine with an integrated medical approach in private practice beginning in 2000. He worked at the University Hospital of Munich in the fields of geriatrics and neuromculoskeletal diseases. During this time, he was a clinical trial investigator in multiple Phase 3 studies, including studies sponsored by Merck Sharp & Dohme, Merck, Boehringer Mannheim, Roche, Servier and Sanofi. He received his human medicine degree at the University of Munich and Doctor of Osteopathic Medicine (D.O.) from the German American Academy for Osteopathy, or DAAO, a member of the European Register for Osteopathic Physicians, or EROP, at the Philadelphia College of Osteopathic Medicine. - Peter Donhauser在临床研究方面拥有20多年的专业知识，之后于2000年开始在私人执业中以综合医疗方法从事整骨医学。他曾在慕尼黑大学医院从事老年医学和神经肌肉骨骼疾病领域的工作。在此期间，他是多项3期研究的临床试验研究者，包括由默沙东 Sharp & Dohme、默沙东、勃林格曼海姆、罗氏、施维雅和赛诺菲赞助的研究。他在慕尼黑大学获得人类医学学位，并在费城整骨医学学院的德国美国整骨医学研究院（DAAO）获得整骨医学博士（D.O.），这是欧洲整骨医师名册（European Register for Osteopathic Physicians，简称EROP）的成员。
- Peter Donhauser had more than 20 years of expertise in clinical research prior to practicing osteopathic medicine with an integrated medical approach in private practice beginning in 2000. He worked at the University Hospital of Munich in the fields of geriatrics and neuromculoskeletal diseases. During this time, he was a clinical trial investigator in multiple Phase 3 studies, including studies sponsored by Merck Sharp & Dohme, Merck, Boehringer Mannheim, Roche, Servier and Sanofi. He received his human medicine degree at the University of Munich and Doctor of Osteopathic Medicine (D.O.) from the German American Academy for Osteopathy, or DAAO, a member of the European Register for Osteopathic Physicians, or EROP, at the Philadelphia College of Osteopathic Medicine.
- Claus van der Velden
-
Claus van der Velden在管理、会计、内部控制、信息安全和风险管理方面拥有丰富的专业知识。2021年5月至今，担任德国区域电信提供商NetCologne GmbH的董事总经理（首席财务官）。2011年7月至2021年5月，他在德国数字媒体上市公司Stroeer SE & Co KGaA担任管理会计、内部审计和风险管理的企业负责人。作为Stroeer SE & Co KGaA的前任内部审计主管，van der Velden博士在信息安全风险评估领域，以及应对信息安全威胁所需的内部控制工具、流程和政策方面拥有经验。Previoly，Dr. van der Velden曾担任全球营养成分和特种化学品的全球供应商Cognis的Nutrition & Health Biness部门的企业Biness Control总监。在这一职位上，他还是合规代表和全球领导团队成员。在巴斯夫收购Cognis后，他负责巴斯夫营养与健康部门的管理会计流程，为食品和医疗保健行业开发和生产大部分为天然的SCE成分。van der Velden博士的职业生涯始于一家国际营销和战略咨询公司的战略顾问。他曾在基尔和斯德哥尔摩学习，并在基尔大学获得经济学学位，后来在WHU Otto Beisheim管理学院获得BINES管理博士学位，他还在那里教授经济学。
Claus van der Velden has significant expertise in management, accounting, internal controls, information security and risk management. Since May 2021, he has served as Managing Director (Chief Financial Officer) of NetCologne GmbH, a regional telecommunication provider in Germany. From July 2011 to May 2021, he served as corporate head of Management Accounting, Internal Audit and Risk Management at Stroeer SE & Co KGaA, a publicly listed German digital media company. As the prior head of internal audit at Stroeer SE & Co KGaA, Dr. van der Velden has experience in the area of information security risk assessment, and the internal control tools, processes, and policies needed to counter information security threats. Previoly, Dr. van der Velden served as the Director of Corporate Biness Controlling for the Nutrition & Health biness unit at Cognis, a worldwide supplier of global nutritional ingredients and specialty chemicals. In this position, he was also a compliance representative and a member of the global leadership team. After the acquisition of Cognis by BASF, he was responsible for the management accounting processes of the BASF Nutrition & Health division, developing and producing mostly natural sce ingredients for the food and healthcare indtries. Dr. van der Velden started his career as a strategy consultant at an international marketing and strategy consultancy firm. He studied in Kiel and Stockholm and received a degree in economics from the University of Kiel and later obtained his doctorate in biness management from the WHU Otto Beisheim School of Management where he also previoly taught economics. - Claus van der Velden在管理、会计、内部控制、信息安全和风险管理方面拥有丰富的专业知识。2021年5月至今，担任德国区域电信提供商NetCologne GmbH的董事总经理（首席财务官）。2011年7月至2021年5月，他在德国数字媒体上市公司Stroeer SE & Co KGaA担任管理会计、内部审计和风险管理的企业负责人。作为Stroeer SE & Co KGaA的前任内部审计主管，van der Velden博士在信息安全风险评估领域，以及应对信息安全威胁所需的内部控制工具、流程和政策方面拥有经验。Previoly，Dr. van der Velden曾担任全球营养成分和特种化学品的全球供应商Cognis的Nutrition & Health Biness部门的企业Biness Control总监。在这一职位上，他还是合规代表和全球领导团队成员。在巴斯夫收购Cognis后，他负责巴斯夫营养与健康部门的管理会计流程，为食品和医疗保健行业开发和生产大部分为天然的SCE成分。van der Velden博士的职业生涯始于一家国际营销和战略咨询公司的战略顾问。他曾在基尔和斯德哥尔摩学习，并在基尔大学获得经济学学位，后来在WHU Otto Beisheim管理学院获得BINES管理博士学位，他还在那里教授经济学。
- Claus van der Velden has significant expertise in management, accounting, internal controls, information security and risk management. Since May 2021, he has served as Managing Director (Chief Financial Officer) of NetCologne GmbH, a regional telecommunication provider in Germany. From July 2011 to May 2021, he served as corporate head of Management Accounting, Internal Audit and Risk Management at Stroeer SE & Co KGaA, a publicly listed German digital media company. As the prior head of internal audit at Stroeer SE & Co KGaA, Dr. van der Velden has experience in the area of information security risk assessment, and the internal control tools, processes, and policies needed to counter information security threats. Previoly, Dr. van der Velden served as the Director of Corporate Biness Controlling for the Nutrition & Health biness unit at Cognis, a worldwide supplier of global nutritional ingredients and specialty chemicals. In this position, he was also a compliance representative and a member of the global leadership team. After the acquisition of Cognis by BASF, he was responsible for the management accounting processes of the BASF Nutrition & Health division, developing and producing mostly natural sce ingredients for the food and healthcare indtries. Dr. van der Velden started his career as a strategy consultant at an international marketing and strategy consultancy firm. He studied in Kiel and Stockholm and received a degree in economics from the University of Kiel and later obtained his doctorate in biness management from the WHU Otto Beisheim School of Management where he also previoly taught economics.
- Jiong Ma
-
Jiong Ma在投资、建设和扩展公司方面拥有超过25年的经验，对数字健康、技术和新能源转型领域的创新产品发布具有专注力。马博士自2024年7月起担任Phoenix Venture Partners的普通合伙人。自2022年2月起担任SES AI公司（纽约证券交易所代码：SES）董事，自2023年起担任首席独立董事会董事。她还是薪酬委员会的主席，并且是SES的审计、提名和战略投资委员会的成员。马博士曾于2008年至2020年担任Braemar Energy Ventures（“Braemar”）的高级合伙人和投资委员会成员。在Braemar期间，马博士领导了超过15家公司的投资，这些公司涉及resce efficiency、e mobility、indtrial digitalization、可再生能源或深度科技，并通过并购和IPO实现了多次成功退出。马博士在包括信息安全在内的科技行业拥有丰富的知识和专长。在加入Braemar Energy Ventures之前，2004年至2007年，她在全球私募股权公司3i Group的风险投资集团Capital Group任职，在那里她领导了对Digital Health、TMT和清洁技术等多个阶段的投资。在3i的风险投资集团Capital Group之前，马博士曾于1997年至2004年在朗讯科技和贝尔实验室担任多个高级职位。她的职责包括在产品组合战略、光学和数据网络的新产品发布以及研究和产品开发方面担任领导角色。马博士还是光纤网络公司Onetta Inc.的创始团队成员。她拥有科罗拉多大学博尔德分校的电气和计算机工程博士学位，以及伍斯特理工学院的电气工程硕士学位。马博士是考夫曼研究员。
Jiong Ma has over 25 years of experience in investing, building, and scaling of companies with a foc on innovative product launches in digital health, technology and the new energy transition. Dr. Ma has been a General Partner of Phoenix Venture Partners since July 2024. She has served as director of SES AI Corporation (NYSE: SES) since February 2022 and has served as Lead Independent Board Director beginning in 2023. She also chairs the Compensation Committee, and is a member of Audit, Nominating, and Strategic Investment Committee of SES. Dr. Ma served as senior partner and a member of the investment committee at Braemar Energy Ventures ("Braemar") from 2008 to 2020. While at Braemar, Dr. Ma led investments in more than 15 companies involved in either resce efficiency, e mobility, indtrial digitalization, renewable energy, or deep tech, and has achieved multiple successful exits through M&A and IPO. Dr. Ma has significant knowledge and expertise in the technology industry, including information security. Prior to Braemar Energy Ventures, she was with the Venture Capital Group at 3i Group, a global private equity firm, from 2004 to 2007 where she led investments across multiple stages in Digital Health, TMT and Cleantech. Preceding the Venture Capital Group at 3i, Dr. Ma held several senior positions at Lucent Technologies and Bell Labs from 1997 to 2004. Her responsibilities included lead roles in product portfolio strategy, new product launches for Optical and Data Networking, and research and product development. Dr. Ma was also a founding team member of Onetta Inc., a fiber networks company. She has a PhD in Electrical and Computer Engineering from the University of Colorado Boulder and an MS in Electrical Engineering from Worcester Polytechnic Institute. Dr. Ma is a Kauffman Fellow. - Jiong Ma在投资、建设和扩展公司方面拥有超过25年的经验，对数字健康、技术和新能源转型领域的创新产品发布具有专注力。马博士自2024年7月起担任Phoenix Venture Partners的普通合伙人。自2022年2月起担任SES AI公司（纽约证券交易所代码：SES）董事，自2023年起担任首席独立董事会董事。她还是薪酬委员会的主席，并且是SES的审计、提名和战略投资委员会的成员。马博士曾于2008年至2020年担任Braemar Energy Ventures（“Braemar”）的高级合伙人和投资委员会成员。在Braemar期间，马博士领导了超过15家公司的投资，这些公司涉及resce efficiency、e mobility、indtrial digitalization、可再生能源或深度科技，并通过并购和IPO实现了多次成功退出。马博士在包括信息安全在内的科技行业拥有丰富的知识和专长。在加入Braemar Energy Ventures之前，2004年至2007年，她在全球私募股权公司3i Group的风险投资集团Capital Group任职，在那里她领导了对Digital Health、TMT和清洁技术等多个阶段的投资。在3i的风险投资集团Capital Group之前，马博士曾于1997年至2004年在朗讯科技和贝尔实验室担任多个高级职位。她的职责包括在产品组合战略、光学和数据网络的新产品发布以及研究和产品开发方面担任领导角色。马博士还是光纤网络公司Onetta Inc.的创始团队成员。她拥有科罗拉多大学博尔德分校的电气和计算机工程博士学位，以及伍斯特理工学院的电气工程硕士学位。马博士是考夫曼研究员。
- Jiong Ma has over 25 years of experience in investing, building, and scaling of companies with a foc on innovative product launches in digital health, technology and the new energy transition. Dr. Ma has been a General Partner of Phoenix Venture Partners since July 2024. She has served as director of SES AI Corporation (NYSE: SES) since February 2022 and has served as Lead Independent Board Director beginning in 2023. She also chairs the Compensation Committee, and is a member of Audit, Nominating, and Strategic Investment Committee of SES. Dr. Ma served as senior partner and a member of the investment committee at Braemar Energy Ventures ("Braemar") from 2008 to 2020. While at Braemar, Dr. Ma led investments in more than 15 companies involved in either resce efficiency, e mobility, indtrial digitalization, renewable energy, or deep tech, and has achieved multiple successful exits through M&A and IPO. Dr. Ma has significant knowledge and expertise in the technology industry, including information security. Prior to Braemar Energy Ventures, she was with the Venture Capital Group at 3i Group, a global private equity firm, from 2004 to 2007 where she led investments across multiple stages in Digital Health, TMT and Cleantech. Preceding the Venture Capital Group at 3i, Dr. Ma held several senior positions at Lucent Technologies and Bell Labs from 1997 to 2004. Her responsibilities included lead roles in product portfolio strategy, new product launches for Optical and Data Networking, and research and product development. Dr. Ma was also a founding team member of Onetta Inc., a fiber networks company. She has a PhD in Electrical and Computer Engineering from the University of Colorado Boulder and an MS in Electrical Engineering from Worcester Polytechnic Institute. Dr. Ma is a Kauffman Fellow.
- Axel Paeger
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
高管简历
中英对照 | 中文 | 英文- Christopher Missling
Christopher Missling在大型制药，生物技术产业和投资银行业务方面有着20多年的医疗行业经验。最近，从2007年3月到被公司任命之前，他曾担任纽约Brimberg & Co.医疗保健投资银行主管。此外， Missling还担任过Curis, Inc. NASDAQ：CRIS 和 ImmunoGen, Inc. （NASDAQ：IMGN）首席财务官。Missling持有Munich大学理学硕士和博士学位；Northwestern 大学Kellogg School of Management和WHU Otto Beisheim School of Management工商管理硕士学位。
Christopher Missling has over tnty years of healthcare indtry experience in big pharmaceutical, biotech and investment banking prior to joining Anavex. Most recently, from March 2007 until his appointment by Company, Dr. Missling served as the head of healthcare investment banking at Brimberg & Co. in New York, New York. In addition, Dr. Missling served as the Chief Financial Officer of Curis, Inc. (NASDAQ: CRIS) and ImmunoGen, Inc. (NASDAQ: IMGN). Dr. Missling earned his MS and PhD from the University of Munich and an MBA from Northstern University Kellogg School of Management and WHU Otto Beisheim School of Management.- Christopher Missling在大型制药，生物技术产业和投资银行业务方面有着20多年的医疗行业经验。最近，从2007年3月到被公司任命之前，他曾担任纽约Brimberg & Co.医疗保健投资银行主管。此外， Missling还担任过Curis, Inc. NASDAQ：CRIS 和 ImmunoGen, Inc. （NASDAQ：IMGN）首席财务官。Missling持有Munich大学理学硕士和博士学位；Northwestern 大学Kellogg School of Management和WHU Otto Beisheim School of Management工商管理硕士学位。
- Christopher Missling has over tnty years of healthcare indtry experience in big pharmaceutical, biotech and investment banking prior to joining Anavex. Most recently, from March 2007 until his appointment by Company, Dr. Missling served as the head of healthcare investment banking at Brimberg & Co. in New York, New York. In addition, Dr. Missling served as the Chief Financial Officer of Curis, Inc. (NASDAQ: CRIS) and ImmunoGen, Inc. (NASDAQ: IMGN). Dr. Missling earned his MS and PhD from the University of Munich and an MBA from Northstern University Kellogg School of Management and WHU Otto Beisheim School of Management.
- Sandra Boenisch
Sandra Boenisch，她是在加拿大美国有14年的会计、审计、和财务报告经验的特许专业会计师（CPA），加拿大注册会计师协会（CGA）。她是一个独立的顾问。2012年1月以来她为美国和加拿大一系列上市公司提供财务报告服务。从2008年到2012年，她被受雇于 BDO Canada LLP （Vancouver, BC）。她在此高级会计，后来晋升为审计确信度经理。她专注于美国和加拿大上市公司的鉴证业务管理。此前2001年以来，她在上市会计公司任职。作为一个独立的顾问，她获得了相当多的金融、治理和监管合规经验。她持有Laurentian University的商学士学位。
Sandra Boenisch is a Chartered Professional Accountant (CPA, CGA) with approximately 20 years of accounting, audit and financial reporting experience in a variety of indtries, both in the United States and Canada. Ms. Boenisch was an independent consultant, providing financial reporting services to a range of public companies in the United States and Canada since January 2012. From 2008 until 2012, Ms. Boenisch was employed at BDO Canada LLP (Vancouver, BC) where she was hired as a Senior Accountant and was later promoted to Manager, Audit Assurance. Ms. Boenisch specialized in managing assurance engagements for public companies in the United States and Canada. Prior to that, Ms. Boenisch worked for another public accounting firm from 2001 to 2008. As an independent consultant, Ms. Boenisch has acquired considerable experience in finance, governance, and regulatory compliance. She holds a BComm from Laurentian University.- Sandra Boenisch，她是在加拿大美国有14年的会计、审计、和财务报告经验的特许专业会计师（CPA），加拿大注册会计师协会（CGA）。她是一个独立的顾问。2012年1月以来她为美国和加拿大一系列上市公司提供财务报告服务。从2008年到2012年，她被受雇于 BDO Canada LLP （Vancouver, BC）。她在此高级会计，后来晋升为审计确信度经理。她专注于美国和加拿大上市公司的鉴证业务管理。此前2001年以来，她在上市会计公司任职。作为一个独立的顾问，她获得了相当多的金融、治理和监管合规经验。她持有Laurentian University的商学士学位。
- Sandra Boenisch is a Chartered Professional Accountant (CPA, CGA) with approximately 20 years of accounting, audit and financial reporting experience in a variety of indtries, both in the United States and Canada. Ms. Boenisch was an independent consultant, providing financial reporting services to a range of public companies in the United States and Canada since January 2012. From 2008 until 2012, Ms. Boenisch was employed at BDO Canada LLP (Vancouver, BC) where she was hired as a Senior Accountant and was later promoted to Manager, Audit Assurance. Ms. Boenisch specialized in managing assurance engagements for public companies in the United States and Canada. Prior to that, Ms. Boenisch worked for another public accounting firm from 2001 to 2008. As an independent consultant, Ms. Boenisch has acquired considerable experience in finance, governance, and regulatory compliance. She holds a BComm from Laurentian University.